- Home
- Na Leber Congenital Amaurosis Market
NA Leber Congenital Amaurosis Market - Industry Trends and Forecast to 2029
- Published Date: September, 2022 | Report ID: CLS-500 | No of pages: 188 | Format:
North America leber congential amaurosis market is projected to register a CAGR of 4.4% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2022 to 2029
Market Segmentation:
North America Leber Congenital Amaurosis Market, By Disease (Infantile Type, Juvenile Type and Other), Type (Therapy and Diagnosis), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare and Others), Distribution Channel (Direct Tender and Retail Sales), Country (U.S., Canada, Mexico) Industry Trends and Forecast to 2029
Some of the major factors contributing to the growth of the North America leber congential amaurosis market are:
Rising prevalence of leber congenital amaurosis in children.
Increasing healthcare expenditure
Market Players:
The key market players for North America leber congential amaurosis market are listed below:
Invitae Corporation.
Johnson & Johnson Services, Inc.
Spark Therapeutics, Inc.
LKC TECHNOLOGIES, INC.
Amarantus Bioscience Holdings, Inc.
Sucampo Pharmaceuticals, Inc.
Orphagen Pharmaceuticals, Inc.
TABLE OF CONTENT
TABLE OF CONTENTS 1 INTRODUCTION 43 1.1 OBJECTIVES OF THE STUDY 43 1.2 MARKET DEFINITION 43 1.3 OVERVIEW OF NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET 43 1.4 LIMITATIONS 44 1.5 MARKETS COVERED 45 2 MARKET SEGMENTATION 48 2.1 MARKETS COVERED 48 2.2 GEOGRAPHICAL SCOPE 49 2.3 YEARS CONSIDERED FOR THE STUDY 50 2.4 CURRENCY AND PRICING 50 2.5 DBMR TRIPOD DATA VALIDATION MODEL 51 2.6 MULTIVARIATE MODELLING 54 2.7 DISEASE TYPE LIFELINE CURVE 54 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 55 2.9 DBMR MARKET POSITION GRID 56 2.10 MARKET END USER COVERAGE GRID 57 2.11 VENDOR SHARE ANALYSIS 58 2.12 SECONDARY SOURCES 59 2.13 ASSUMPTIONS 59 3 EXECUTIVE SUMMARY 60 4 PREMIUM INSIGHTS 63 4.1 PIPELINE ANALYSIS FOR NORTH AMERICA LEBER CONGENTIAL AMAUROSIS MARKET 65 4.2 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: REGULATIONS 67 4.3 PESTEL ANALYSIS 70 4.4 PORTERS FIVE FORCES 71 5 EPIDEMIOLOGY 72 6 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET, MARKET OVERVIEW 73 6.1 DRIVERS 75 6.1.1 INCREASE IN INCIDENCE AND PREVALENCE OF RPE65 GENE-MEDIATED IN RETINAL DISEASES 75 6.1.2 INCREASE IN PIPELINE PRODUCTS AND CLINICAL TRIALS 78 6.1.3 INCREASE IN STRATEGIC INITIATIVE BY KEY PLAYER 84 6.2 RESTRAINTS 85 6.2.1 LACK OF QUALIFIED PROFESSIONALS 85 6.2.2 HIGH COSTS ASSOCIATED WITH TREATMENT AND PROCEDURE 86 6.3 OPPORTUNITIES 87 6.3.1 INCREASE IN GOVERNMENT INITIATIVES TOWARD LEBER CONGENITAL AMAUROSIS 87 6.3.2 INCREASE IN THE TREATMENT-SEEKING RATE 87 6.3.3 FAVOURABLE REIMBURSEMENT POLICIES FOR THE TREATMENT 88 6.4 CHALLENGES 89 6.4.1 RISKS ASSOCIATED WITH LEBER CONGENITAL AMAUROSIS GENE THERAPY 89 6.4.2 STRINGENT GOVERNMENT REGULATIONS FOR GENE THERAPY PRODUCTS 89 7 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE 90 7.1 OVERVIEW 91 7.2 INFANTILE TYPE 94 7.3 JUVENILE TYPE 94 7.4 OTHERS 95 8 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE 96 8.1 OVERVIEW 97 8.2 THERAPY 100 8.2.1 GENE THERAPY 101 8.2.1.1 LUXTURNA 101 8.2.2 RETINAL PROSTHETIC 101 8.2.3 NEUROPROTECTIVE AGENTS 101 8.2.3.1 VITAMIN A PALMITATE 102 8.2.3.2 DOCOSAHEXAENOIC ACID 102 8.2.3.3 LUTEIN 102 8.2.3.4 OTHERS 102 8.2.4 OTHERS 102 8.3 DIAGNOSIS 103 8.3.1 CLINICAL DIAGNOSIS 104 8.3.1.1 ELECTROPHYSIOLOGICAL TESTS 104 8.3.1.1.1 FULL-FIELD ELECTRORETINOGRAM (ERG) 105 8.3.1.1.2 DARK ADAPTOMETRY (DA) 105 8.3.1.2 RETINAL IMAGING 105 8.3.1.2.1 OPTICAL COHERENCE TOMOGRAPHY (OCT) 105 8.3.1.2.2 FUNDUS AUTOFLUORESCENCE 106 8.3.1.2.3 SCANNING LASER OPHTHALMOSCOPY (SLO) 106 8.3.1.2.4 ADAPTIVE OPTICS (AO) IMAGING 106 8.3.1.2.5 CONVENTIONAL COLOR FUNDUS IMAGING 106 8.3.1.3 VISUAL FIELD TEST 106 8.3.1.3.1 COMPUTERIZED VISUAL FIELD TESTS 106 8.3.1.3.2 MANUAL FIELD TEST 106 8.3.1.4 CLINICAL EYE EXAMINATION 107 8.3.1.4.1 SLIT LAMP 107 8.3.1.4.2 INDIRECT OPHTHALMOSCOPY 107 8.3.1.4.3 REFRACTION TEST 107 8.3.1.4.4 DILATION EXAM 107 8.3.1.5 OTHERS 107 8.3.2 GENETIC DIAGNOSIS 108 9 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER 109 9.1 OVERVIEW 110 9.2 HOSPITALS 113 9.3 SPECIALITY CLINICS 114 9.4 AMBULATORY SURGICAL CENTERS 115 9.5 HOME HEALTHCARE 116 9.6 OTHERS 117 10 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL 118 10.1 OVERVIEW 119 10.2 RETAIL SALES 122 10.2.1.1 HOSPITAL PHARMACIES 123 10.2.1.2 RETAIL PHARMACIES 123 10.2.1.3 OTHERS 123 10.3 DIRECT TENDER 123 11 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET, BY REGION 124 11.1 NORTH AMERICA 125 11.1.1 U.S. 132 11.1.2 CANADA 136 11.1.3 MEXICO 140 12 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: COMPANY LANDSCAPE 144 12.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 144 13 SWOT ANALYSIS 145 14 COMPANY PROFILE 146 14.1 SPARK THERAPEUTICS, INC 146 14.1.1 COMPANY SNAPSHOT 146 14.1.2 COMPANY SHARE ANALYSIS 146 14.1.3 PRODUCT PORTFOLIO 147 14.1.4 RECENT DEVELOPMENT 147 14.1.4.1 EU AUTHORIZATION 147 14.2 OPTOS 148 14.2.1 COMPANY SNAPSHOT 148 14.2.2 COMPANY SHARE ANALYSIS 148 14.2.3 PRODUCT PORTFOLIO 149 14.2.4 RECENT DEVELOPMENT 149 14.2.4.1 PRODUCT APPROVAL 149 14.3 CD GENOMICS 150 14.3.1 COMPANY SNAPSHOT 150 14.3.2 COMPANY SHARE ANALYSIS 150 14.3.3 PRODUCT PORTFOLIO 151 14.3.4 RECENT DEVELOPMENT 151 14.4 BLUEPRINTS GENETICS OY (A SUBSIDIARY OF QUEST DIAGNOSTICS) 152 14.4.1 COMPANY SNAPSHOT 152 14.4.2 REVENUE ANALYSIS 152 14.4.3 COMPANY SHARE ANALYSIS 153 14.4.4 PRODUCT PORTFOLIO 153 14.4.5 RECENT DEVELOPMENTS 153 14.4.5.1 COLLABORATION 153 14.5 LKC TECHNOLOGIES, INC 154 14.5.1 COMPANY SNAPSHOT 154 14.5.2 COMPANY SHARE ANALYSIS 154 14.5.3 PRODUCT PORTFOLIO 155 14.5.4 RECENT DEVELOPMENT 155 14.5.4.1 PRODUCT APPROVAL 155 14.5.5 PRODUCT APPROVAL 155 14.6 AGTC 156 14.6.1 COMPANY SNAPSHOT 156 14.6.2 REVENUE ANALYSIS 156 14.6.3 PRODUCT PORTFOLIO 157 14.6.4 RECENT DEVELOPMENTS 157 14.6.4.1 AGREEMENT 157 14.7 ALLERGAN (A SUBSIDIARY OF ABBVIE INC.) 158 14.7.1 COMPANY SNAPSHOT 158 14.7.2 REVENUE ANALYSIS 158 14.7.3 PRODUCT PORTFOLIO 159 14.7.4 RECENT DEVELOPMENTS 159 14.8 ASTELLAS PHARMA INC. 160 14.8.1 COMPANY SNAPSHOT 160 14.8.2 REVENUE ANALYSIS 160 14.8.3 PRODUCT PORTFOLIO 161 14.8.4 RECENT DEVELOPMENT 161 14.9 ATSENA THERAPEUTICS 162 14.9.1 COMPANY SNAPSHOT 162 14.9.2 PRODUCT PORTFOLIO 162 14.9.3 RECENT DEVELOPMENT 162 14.10 CENTOGENE N.V. 163 14.10.1 COMPANY SNAPSHOT 163 14.10.2 REVENUE ANALYSIS 163 14.10.3 PRODUCT PORTFOLIO 164 14.10.4 RECENT DEVELOPMENT 164 14.10.4.1 PRODUCT LAUNCH 164 14.11 COAVE THERAPEUTICS 165 14.11.1 COMPANY SNAPSHOT 165 14.11.2 PRODUCT PORTFOLIO 165 14.11.3 RECENT DEVELOPMENT 165 14.12 EDITAS MEDICINE 166 14.12.1 COMPANY SNAPSHOT 166 14.12.2 REVENUE ANALYSIS 166 14.12.3 PRODUCT PORTFOLIO 167 14.12.4 RECENT DEVELOPMENTS 167 14.12.4.1 DATA & TRAIL DATA PRESENTATION 167 14.13 ELUMINEX BIOSCIENCES 168 14.13.1 COMPANY SNAPSHOT 168 14.13.2 PRODUCT PORTFOLIO 168 14.13.3 RECENT DEVELOPMENT 168 14.14 GYROSCOPE THERAPEUTICS LIMITED 169 14.14.1 COMPANY SNAPSHOT 169 14.14.2 PRODUCT PORTFOLIO 169 14.14.3 RECENT DEVELOPMENTS 169 14.15 INVITAE CORPORATION 171 14.15.1 COMPANY SNAPSHOT 171 14.15.2 REVENUE ANALYSIS 171 14.15.3 PRODUCT PORTFOLIO 172 14.15.4 RECENT DEVELOPMENTS 172 14.15.4.1 NEW FACILITY 172 14.15.4.2 EXPANSION 172 14.16 IVERIC BIO. 173 14.16.1 COMPANY SNAPSHOT 173 14.16.2 PRODUCT PORTFOLIO 173 14.16.3 RECENT DEVELOPMENT 173 14.17 KUBOTA PHARMACEUTICAL HOLDINGS CO., LTD. 174 14.17.1 COMPANY SNAPSHOT 174 14.17.2 REVENUE ANALYSIS 174 14.17.3 PRODUCT PORTFOLIO 175 14.17.4 RECENT DEVELOPMENTS 175 14.18 MEIRAGTX LIMITED 176 14.18.1 COMPANY SNAPSHOT 176 14.18.2 PRODUCT PORTFOLIO 176 14.18.3 RECENT DEVELOPMENT 176 14.19 METROVISION 178 14.19.1 COMPANY SNAPSHOT 178 14.19.2 PRODUCT PORTFOLIO 178 14.19.3 RECENT DEVELOPMENT 178 14.19.3.1 FDA CLEARANCE APPROVAL 178 14.20 OCUGEN INC. 179 14.20.1 COMPANY SNAPSHOT 179 14.20.2 PRODUCT PORTFOLIO 179 14.20.3 RECENT DEVELOPMENT 179 14.21 OKUVISION 180 14.21.1 COMPANY SNAPSHOT 180 14.21.2 PRODUCT PORTFOLIO 180 14.21.3 RECENT DEVELOPMENTS 180 14.21.3.1 APPROVAL 180 14.22 PROQR THERAPEUTICS 181 14.22.1 COMPANY SNAPSHOT 181 14.22.2 PRODUCT PORTFOLIO 181 14.22.3 RECENT DEVELOPMENTS 181 14.23 REGENXBIO INC. 182 14.23.1 COMPANY SNAPSHOT 182 14.23.2 REVENUE ANALYSIS 182 14.23.3 PRODUCT PORTFOLIO 183 14.23.4 RECENT DEVELOPMENTS 183 14.24 SPARINGVISION 184 14.24.1 COMPANY SNAPSHOT 184 14.24.2 PRODUCT PORTFOLIO 184 14.24.3 RECENT DEVELOPMENTS 184 15 QUESTIONNAIRE 185 16 RELATED REPORTS 188Segmentation
Short Description North America Leber Congenital Amaurosis Market, By Disease (Infantile Type, Juvenile Type and Other), Type (Therapy and Diagnosis), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare and Others), Distribution Channel (Direct Tender and Retail Sales), Country (U.S., Canada, Mexico) Industry Trends and Forecast to 2029 Market Definition: Leber congenital amaurosis (LCA) is defined as a type of disorder of the eye which mainly affects the retina. Retina is the specific tissue at the back of the eye responsible for the detection of light and colour. Leber congenital amaurosis (LCA) is a rare inherited eye disease that appears at birth or in the first few months of life. It affects about 1 in 40,000 newborns. People with this disorder typically have severe visual impairment beginning in infancy. The visual impairment tends to be stable, although it may worsen very slowly over time. Market Segmentation: North America leber congenital amaurosis market is categorized into four notable segments which are based on disease type, type, end user and distribution channel On the basis of disease type, the leber congenital amaurosis market is segmented into infantile type, juvenile type, and others. On the basis of type, the leber congenital amaurosis market is segmented into diagnosis and therapy. On the basis of end user, the leber congenital amaurosis market is segmented into hospitals, specialty clinics, ambulatory surgical centers, home healthcare, and others. On the basis of distribution channel, the leber congenital amaurosis market is segmented into hospital pharmacies, retail pharmacies and others. Market Players The key market players for North America leber congenital amaurosis market are listed below: Invitae Corporation Spark Therapeutics, Inc. LKC TECHNOLOGIES, INC CENTOGENE N.V. Optos, Metrovision Blueprint Genetics Oy (A Subsidiary of Quest Diagnostics) CD Genomics ProQR Therapeutics OCUGEN, INC. MeiraGTx Limited Coave Therapeutics IVERIC bio, Inc. Atsena Therapeutics Editas Medicine Eluminex Biosciences Okuvision Astellas Pharma Inc. Allergan (A Subsidiary of Abbvie Inc.) AGTC Gyroscope Therapeutics Limited SparingVision Kubota Pharmaceutical Holdings Co. Ltd. REGENXBIO IncMethodology
Why Choose Us
24 * 7 Access to Analyst :
Get your pre and post sales queries resolved by our Subject matter experts.
Customization :
We will assist you to customize the report to fit your research needs.
Assured Quality :
Our prime focus is to provide qualitative and accurate data.
Free sample report :
Feel free to order a sample report before purchase.
Security :
Your personal and confidential information is safe and secured.
© 2025 Cognate Lifesciences. All Rights Reserved.